Prevalence of FV Leiden mutation, prothrombin 20210A allele, and FXIII-A Leu34 allele in patients with thrombophilia and healthy controls
| . | Controls . | Patients . |
|---|---|---|
| n | 288 | 273 |
| Age (SD) | 30.3 (10.9) | 35.2 (11.7) |
| Sex (male/female) | 94/194 | 89/184 |
| FV Leiden mutation | ||
| Wild-type | 258 (89.6%) | 194 (71.1%) |
| Heterozygous | 30 (10.4%) | 66 (24.2%) |
| Homozygous | 0 (0%) | 13 (4.7%) |
| Allele frequency | 5.2% (3.4-7.0%) | 16.8% (13.7-20.0%) |
| OR (95% CI)* | 3.50 (2.20-5.53) | |
| FII 20210A allele | ||
| Wild-type | 281 (97.6%) | 256 (93.8%) |
| Heterozygous | 7 (2.4%) | 16 (5.9%) |
| Homozygous | 0 (0%) | 1 (0.3%) |
| Allele frequency | 1.2% (0.3-2.1%) | 3.3% (1.8-4.8%) |
| OR (95% CI)* | 2.67 (1.08-6.55) | |
| FXIII-A Val34Leu polymorphism | ||
| Wild-type | 158 (54.9%) | 144 (52.7%) |
| Heterozygous | 111 (38.5%) | 111 (40.7%) |
| Homozygous | 19 (6.6%) | 18 (6.6%) |
| Allele frequency | 25.9% (22.3-29.5%) | 26.9% (23.2-30.6%) |
| OR (95% CI)* | 1.09 (0.78-1.52) | |
| OR (95% CI)† | 1.04 (0.53-2.06) |
| . | Controls . | Patients . |
|---|---|---|
| n | 288 | 273 |
| Age (SD) | 30.3 (10.9) | 35.2 (11.7) |
| Sex (male/female) | 94/194 | 89/184 |
| FV Leiden mutation | ||
| Wild-type | 258 (89.6%) | 194 (71.1%) |
| Heterozygous | 30 (10.4%) | 66 (24.2%) |
| Homozygous | 0 (0%) | 13 (4.7%) |
| Allele frequency | 5.2% (3.4-7.0%) | 16.8% (13.7-20.0%) |
| OR (95% CI)* | 3.50 (2.20-5.53) | |
| FII 20210A allele | ||
| Wild-type | 281 (97.6%) | 256 (93.8%) |
| Heterozygous | 7 (2.4%) | 16 (5.9%) |
| Homozygous | 0 (0%) | 1 (0.3%) |
| Allele frequency | 1.2% (0.3-2.1%) | 3.3% (1.8-4.8%) |
| OR (95% CI)* | 2.67 (1.08-6.55) | |
| FXIII-A Val34Leu polymorphism | ||
| Wild-type | 158 (54.9%) | 144 (52.7%) |
| Heterozygous | 111 (38.5%) | 111 (40.7%) |
| Homozygous | 19 (6.6%) | 18 (6.6%) |
| Allele frequency | 25.9% (22.3-29.5%) | 26.9% (23.2-30.6%) |
| OR (95% CI)* | 1.09 (0.78-1.52) | |
| OR (95% CI)† | 1.04 (0.53-2.06) |